A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
about
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
description
im September 2018 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 20 June 2018
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2018
@uk
name
A phase I study of LY3164530, ...... advanced or metastatic cancer
@en
A phase I study of LY3164530, ...... advanced or metastatic cancer
@nl
type
label
A phase I study of LY3164530, ...... advanced or metastatic cancer
@en
A phase I study of LY3164530, ...... advanced or metastatic cancer
@nl
prefLabel
A phase I study of LY3164530, ...... advanced or metastatic cancer
@en
A phase I study of LY3164530, ...... advanced or metastatic cancer
@nl
P2093
P2860
P50
P921
P1476
A phase I study of LY3164530, ...... advanced or metastatic cancer
@en
P2093
Aimee Bence Lin
Amita Patnaik
Drew Rasco
Frank Tsai
Melinda D Willard
Michael Gordon
Muralidhar Beeram
Scott M Hynes
P2860
P2888
P304
P356
10.1007/S00280-018-3623-7
P407
P577
2018-06-20T00:00:00Z